Smallpox

Vaccinia hyperimmune globulin contract awarded

Published in Vaccine Weekly, October 2nd, 2002

Cangene announces that it has been awarded a contract by the United States Centers for Disease Control and Prevention to develop and supply a vaccinia immune globulin (VIg) for use in treating and preventing severe reactions that may be brought on by the administration of the smallpox vaccine.

The contract is for a 5-year period to supply a maximum of 100,000 doses of VIG.

The CDC will order product under this contract on an as-needed basis. The company expects the initial order, of approximately 15,000 doses, to be finalized shortly.

"We are extremely pleased to be able to assist in this vital project. This contract is a result...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-10-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry